Forward looking statements

The materials in this presentation speak only as of the date of these materials, and include forward looking statements about CSL Limited and its related bodies corporate (CSL) financial results and estimates, business prospects and products in research, all of which involve substantial risks and uncertainties, many of which are outside the control of, and are unknown to, CSL. You can identify these forward looking statements by the fact that they use words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “target,” “may,” “assume,” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Factors that could cause actual results to differ materially include: the success of research and development activities, decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; litigation or government investigations, and CSL’s ability to protect its patents and other intellectual property. The statements being made in this presentation do not constitute an offer to sell, or solicitation of an offer to buy, any securities of CSL.

No representation, warranty or assurance (express or implied) is given or made in relation to any forward looking statement by any person (including CSL). In particular, no representation, warranty or assurance (express or implied) is given in relation to any underlying assumption or that any forward looking statement will be achieved. Actual future events may vary materially from the forward looking statements and the assumptions on which the forward looking statements are based.

Subject to any continuing obligations under applicable law or any relevant listing rules of the Australian Securities Exchange, CSL disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations in relation to any forward looking statements or any change in events, conditions or circumstances on which any such statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of CSL since the date of these materials.

Trademarks

Except where otherwise noted, brand names designated by a ™ or ® throughout this presentation are trademarks either owned by and/or licensed to CSL or its affiliates.
Reported Financials

Sales US$5,459 million, up 2% (up 7% @CC\(^1\))
EBIT US$1,758 million, up 7% (up 10% @CC)
  • Adjusted for acquisition costs\(^2\) up 12% @CC
NPAT US$1,379 million, up 6% (up 8% @CC)
  • Adjusted for acquisition costs up 10% @CC
R&D investment US$463 million
EPS US$2.92, up 8% (up 11% @CC)
  • Adjusted for acquisition costs up 13% @CC
Final dividend increased to US$0.66, unfranked (up 10%)
  • Converted to AUD ~$0.90, up 39%

1. Constant Currency (CC) removes the impact of exchange rate movements to facilitate comparability. See end note for further detail.
2. One off costs connected with the acquisition of the Novartis influenza business
Highlights

- Acquisition of Novartis global influenza vaccines business
- bioCSL business turnaround
- Hizentra® - EMA & U.S. FDA approve flexible dosing
- CSL 654 (rIX-FP) – license application submitted in U.S. & EU
- CSL 627 (rFVIII-SC) – license application submitted in U.S.
- CSL 112 (rHDL) – global phase IIb trial recruiting rapidly
- A$950 million share buyback completed
- New buyback* foreshadowed
- New private placement foreshadowed

* CSL reserves the right to suspend or terminate buybacks at any time
Facilities Expansion
Investing for Growth

Recombinant
• Broke ground on rCOAG plant in Lengnau, Switzerland

Plasma
• Completed validation runs for the new Privigen® facility in BMW
• Construction underway for new albumin facility in BMW
• Obtained FDA and other regulatory approvals for the new base fractionation and albumin facility in Kankakee
• Broke ground on a new packaging facility in Marburg, Germany
• Started project to expand Berinert® production capacity

Collections
• 21 centres opened in the USA, plus 1 in Hungary, increasing the fleet in the US to 119 centres, or 128 centres globally
Group Revenue FY15 US$5.6b

Specialty Products 16%
Pharma & Vaccines 8%
Other 8%
Peri-op 8%
Albumin 14%
pd Coag 10%
rFVIII 8%
Hyper IG 3%
SCIG 9%
IVIG 29%

Product Groupings
Broad Sales Reach

North America 41%
Europe 28%
Asia 10%
ROW 13%
bioCSL 8%

FY15 US$5.5b
Outlook for FY16
@ FY15 exchange rates

Financial outlook

- Revenue growth ~ 7% @CC
- Reported NPAT growth ~ 5% @CC

Excludes Novartis influenza vaccine business earnings, acquisition costs & gain on acquisition

- EPS growth will exceed NPAT growth driven by past and current capital management initiatives
- Board to consider a further on-market share buyback* of an amount similar to most recent program

Key variables that could cause actual results to differ materially include: the success of research and development activities, decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; litigation or government investigations; and our ability to protect our patents and other intellectual property.

* CSL reserves the right to suspend or terminate buybacks at any time
CSL Behring
Product Sales up 7% @ CC

Sales for the 12 month period

US$4,926m

US$5,029m

Specialty Products
Immunoglobulins
Albumin
pdCoag
Helixate®

Jun 14
Jun 15
Highlights

Normal IG volume up 8%

IVIG
- Europe
  - CIDP indication driving strong Privigen® demand
- North America
  - Competitive pressure
  - 340B utilisation

SCIG
- Ongoing strong demand for Hizentra® in North American and European markets
- Flexible dosing option and home care convenience underpinning demand
Immunoglobulins
Strong 2H growth

Highlights

2H v 1H 2015
• Total 2H immunoglobulin sales up 13% over 1H @ CC
• ‘Normal’ immunoglobulin sales up 15% over 1H @ CC
• Marketing initiatives

Sales for the 6 month period
Albumin Sales up 12% @ CC

Sales for the 12 month period

China
- Ongoing strong demand
- Improving penetration into Tier 2 & Tier 3 cities

US
- Solid demand continues
- Initiatives focusing on IDNs and large hospitals

Highlights

Jun 14-Jun 15

US$M

US$694m

US$754m

Albumin
Haemophilia Sales up 3% @ CC

Highlights

PdFVIII
- Growth in Beriate® – Brazil, Poland and Germany
- Solid performance from Haemate®/Humate®
- Ongoing transition to recombinant therapies

Helixate®
- Positive results with US patient retention program
- New entrants

Sales for the 12 month period
Specialty Products
Sales up 15% @CC

Sales for the 12 month period

<table>
<thead>
<tr>
<th>Month</th>
<th>Other Specialty Products</th>
<th>Peri-Operative Bleeding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jun 14</td>
<td>US$848m</td>
<td>US$281m</td>
</tr>
<tr>
<td>Jun 15</td>
<td>US$923m</td>
<td>US$303m</td>
</tr>
</tbody>
</table>

Highlights

Kcentra®
- Ongoing strong demand in the U.S.

Berinert® P
- Self administration label driving new patient take-up.

Zemaira®
- New patient acquisition
- Launch of diagnostic testing program driving patient identification
bioCSL
Sales up 11% @CC

Highlights

Business turnaround initiatives driving a return to growth
Influenza sales A$145m
  • Up 18% @CC
  • Increased U.S. sales following the re-establishment of in-house commercial operations
  • First to market in U.S., U.K. and Germany

QIV development
Zostavax* listed on Aust. NIP
Rapivab* commercialisation rights

Sales for the 12 month period

A$M

Jun 14
A$433m
Pharma & vaccines

Jun 15
A$480m
Influenza Vaccine

1 Shown in Australian dollars to highlight operational performance
* Zostavax is a trademark of Merck & Co. Inc.
  Rapivab is a trademark of BioCryst Pharmaceuticals Inc.
CSL Intellectual Property Licensing

Segment Revenue $137m, down 5% @CC

HPV royalties $106m
  - Registration of 9-valent HPV vaccine in US by Merck

CSL362 (anti-IL-3Ra mAb)
  - Exclusive worldwide license with Janssen Biotech Inc to develop and commercialise CSL362
  - Janssen is expected to commence the Phase II study in August 2015
  - Collaborative research to support use in additional indications

CAM3001 (GM-CSFRa)
  - Medimmune/AstraZeneca continue Phase IIb studies in rheumatoid arthritis
  - Positive additional Phase II data
R&D Update

rIX-FP
• rIX-FP Phase III efficacy data supports 7-14 day dosing
• BLA accepted for review by FDA in February
• MAA review procedure commenced by EMA in March

rVIII-SingleChain
• Phase I/III data supports twice weekly dosing
• BLA accepted for review by FDA in July

rVIlia-FP
• Congenital deficiency Phase I/II commenced
• Phase II/III in patients with inhibitors commenced

Hizentra®
• Hizentra® flexible dosing registration in EU and US
• Hizentra® CIDP orphan drug designation in US
Beriplex®
• Commencement of Beriplex® Japan Phase III study

Berinert®
• Pivotal Phase III subcutaneous prophylaxis study recruiting well

Zemaira®/Respreeza® (Alpha1-Proteinase Inhibitor)
• Patients with AATD treated with Respreeza® have lower annual rate of lung density decline
• EMA CHMP recommended granting marketing authorisation for Respreeza® to treat patients with AATD in June

CSL112 (reconstituted High Density Lipoprotein)
• Phase IIa data supports mechanism of action & further development
• Commencement of AEGIS-I Phase IIb study
• Recruiting rapidly
Financial Detail
FY15 Adjusted Profit growth
Up 10% @CC

Adjusted profit up 10% @ CC

FY15
- FX headwind $33m
- One off costs connected with the acquisition of the Novartis influenza business $22m

Operational profit up 6.5% @ CC

FY14
- US Class action settlement
Margin Development

EBITDAR&D* Margin

EBIT Margin

* Earnings before interest, taxes, depreciation, amortisation and research & development
Financial Discipline

Cashflow from operations $1.36 billion
Capital expenditure $414m

<table>
<thead>
<tr>
<th>Working Capital</th>
<th>FY14</th>
<th>FY15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash cycle (days)</td>
<td>281</td>
<td>300</td>
</tr>
<tr>
<td>Free cashflow</td>
<td>$948m</td>
<td>$1,016m</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Financial Strength</th>
<th>FY14</th>
<th>FY15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash on hand</td>
<td>$609m</td>
<td>$557m</td>
</tr>
<tr>
<td>Undrawn debt</td>
<td>$192m</td>
<td>$141m</td>
</tr>
<tr>
<td>Net debt</td>
<td>$1,282m</td>
<td>$1,724m</td>
</tr>
</tbody>
</table>

- Balance Sheet Strength -
Gearing

• Accumulated effect of buybacks since FY05 on current period EPS ~23%

• Gearing target ~1x Net debt/EBITDA
  • Gearing @FY15 ~0.9x

• New on-market share buyback foreshadowed
  • Similar amount to most recent program

• New U.S. private placement foreshadowed
  • Equivalent ~US$500m
Deal closed 31 July 2015

Financial consolidation 1H16

Too early to provide better guidance than that provided in October 2014

- $22m incurred in FY15, majority of balance expected to be incurred in FY16
- Gain on acquisition yet to be determined
- Anticipate providing updated guidance in coming months
Looking Forward

FY16 NPAT growth ~ 5% @ CC

Excl. Novartis influenza vaccine business

Notable items

Ongoing demand for therapies

• Sales expected to grow ~7% @ CC

Investment in growth, incremental ~$50m

• Preparation for rCOAG launches

• New capacity coming on-line

FY17 - anticipate

• Full year rCOAGs sales contribution

• Launch of subcutaneous C1-INH
Core Products

Recombinant Coagulation Factors
rIX-FP, rVIII-SC, rVIIa-FP, rVWF

CSL112
New treatment paradigm in ACS
High margin contributor

Biotech
mAbs in core therapeutic segments

Specialty Products
Multiple high margin contributors: RiaSTAP®, Kcentra®, CytoGam®, Berinert®, Zemaira®

Core Products
Relentless Commitment to lowest cost base;
Operational and Financial Strength and Efficiency.
Continued Ig and Albumin growth through innovation and market expansion
## Group Results

*US Dollars*

<table>
<thead>
<tr>
<th>Full year ended June</th>
<th>Jun 2014</th>
<th>Jun 2015</th>
<th>Jun 2015 at CC¹</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Reported</td>
<td>Reported</td>
<td>at CC¹</td>
<td>%</td>
</tr>
<tr>
<td><strong>Sales</strong></td>
<td>5,335</td>
<td>5,459</td>
<td>5,733</td>
<td>7.5%</td>
</tr>
<tr>
<td>Other Revenue / Income</td>
<td>169</td>
<td>154</td>
<td>156</td>
<td></td>
</tr>
<tr>
<td><strong>Total Revenue / Income</strong></td>
<td>5,504</td>
<td>5,613</td>
<td>5,889</td>
<td>7.0%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Earnings before Interest, Tax, Depreciation &amp; Amortisation</th>
<th>1,832</th>
<th>1,939</th>
<th>1,994</th>
<th>8.8%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Depreciation/Amortisation</td>
<td>195</td>
<td>181</td>
<td>190</td>
<td></td>
</tr>
<tr>
<td><strong>Earnings before Interest and Tax</strong></td>
<td>1,637</td>
<td>1,758</td>
<td>1,804</td>
<td>10.2%</td>
</tr>
<tr>
<td>Net Interest Expense / (Income)</td>
<td>33</td>
<td>44</td>
<td>44</td>
<td></td>
</tr>
<tr>
<td>Tax Expense</td>
<td>297</td>
<td>335</td>
<td>348</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reported Net Profit after Tax</th>
<th>1,307</th>
<th>1,379</th>
<th>1,412</th>
<th>8.0%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acquisition costs²</td>
<td>-</td>
<td>22</td>
<td>22</td>
<td></td>
</tr>
</tbody>
</table>

| Adjusted Net Profit after Tax | 1,307 | 1,401 | 1,434 | 9.7% |

| Total Ordinary Dividend       | 1.13  | 1.24  |       | 10%  |
| Final Dividend (US$)          | 0.60  | 0.66  |       | 10%  |
| Basic EPS (US$)                | 2.70  | 2.92  | 2.99  | 11%  |

---

1. *Constant Currency (CC) removes the impact of exchange rate movements to facilitate comparability. See end note for further detail.*
2. *One off costs connected with the acquisition of the Novartis influenza vaccine business*
# CSL Behring Sales

**US Dollars**

<table>
<thead>
<tr>
<th></th>
<th>FY14 USD$M</th>
<th>FY15 USD$M</th>
<th>FY15 USD$M CC¹</th>
<th>Change %</th>
</tr>
</thead>
<tbody>
<tr>
<td>rFVIII</td>
<td>491</td>
<td>468</td>
<td>495</td>
<td>1%</td>
</tr>
<tr>
<td>pdCoag</td>
<td>573</td>
<td>558</td>
<td>597</td>
<td>4%</td>
</tr>
<tr>
<td>Albumin</td>
<td>694</td>
<td>754</td>
<td>778</td>
<td>12%</td>
</tr>
<tr>
<td>Immunoglobulins</td>
<td>2,320</td>
<td>2,326</td>
<td>2,430</td>
<td>5%</td>
</tr>
<tr>
<td>Specialty Products</td>
<td>848</td>
<td>923</td>
<td>977</td>
<td>15%</td>
</tr>
<tr>
<td>- Peri-operative bleeding</td>
<td>414</td>
<td>450</td>
<td>483</td>
<td>17%</td>
</tr>
<tr>
<td>- Other specialty products</td>
<td>434</td>
<td>473</td>
<td>494</td>
<td>14%</td>
</tr>
<tr>
<td>Total Product Sales</td>
<td>4,926</td>
<td>5,029</td>
<td>5,276</td>
<td>7%</td>
</tr>
<tr>
<td>Other sales (mainly plasma)</td>
<td>15</td>
<td>18</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Sales</td>
<td>4,941</td>
<td>5,047</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. Constant Currency (CC) removes the impact of exchange rate movements to facilitate comparability. See end note for further detail.
Notes

(1) **Constant currency** removes the impact of exchange rate movements to facilitate comparability by restating the current year’s results at the prior year’s rates. This is done in two parts: (a) by converting the current year net profit of entities in the group that have reporting currencies other than US Dollars at the rates that were applicable to the prior year (“translation currency effect”); and (b) by restating material transactions booked by the group that are impacted by exchange rate movements at the rate that would have applied to the transaction if it had occurred in the prior year (“transaction currency effect”). The sum of translation currency effect and transaction currency effect is the amount by which reported net profit is adjusted to calculate the result at constant currency.

**Summary NPAT**

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reported Net Profit after Tax</td>
<td>$1,379.0m</td>
</tr>
<tr>
<td>Translation Currency Effect (a)</td>
<td>$ 91.4m</td>
</tr>
<tr>
<td>Transaction Currency Effect (b)</td>
<td>$(58.6m)</td>
</tr>
<tr>
<td>Constant Currency Net Profit after Tax *</td>
<td>$1,411.8m</td>
</tr>
</tbody>
</table>

(a) Translation Currency Effect $91.4m
Average exchange rates used for calculation in major currencies (twelve months to June 15/June 14) were as follows: USD/EUR (0.82/0.74); USD/CHF(0.94/0.91)

(b) Transaction Currency Effect ($58.6m)
Transaction currency effect is calculated by reference to the applicable prior year exchange rates. The calculation takes into account the timing of sales both internally within the CSL Group (ie from a manufacturer to a distributor) and externally (ie to the final customer) and the relevant exchange rates applicable to each transaction.

**Summary Sales**

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reported Sales</td>
<td>$5,458.6m</td>
</tr>
<tr>
<td>Currency Effect (c)</td>
<td>$274.3m</td>
</tr>
<tr>
<td>Constant Currency Sales *</td>
<td>$5,732.9m</td>
</tr>
</tbody>
</table>

c) Constant Currency Effect $274.3m
Constant currency effect is presented as a single amount due to the complex and interrelated nature of currency impacts on sales.

* Constant Currency Net Profit after Tax and Sales have not been audited or reviewed in accordance with Australian Auditing Standards.